electroCore (NASDAQ:ECOR) Director Thomas Errico Acquires 5,000 Shares

electroCore, Inc. (NASDAQ:ECOR) Director Thomas Errico purchased 5,000 shares of the stock in a transaction dated Monday, September 14th. The stock was purchased at an average cost of $9.82 per share, for a total transaction of $49,100.00. Following the completion of the purchase, the director directly owned 363,904 shares of the company’s stock, valued at approximately $3,573,537.28. The trade was a 1.39% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

electroCore Trading Up 2.5%

ECOR stock opened at $12.29 on Wednesday. The firm has a 50-day moving average of $8.64 and a two-hundred day moving average of $7.74. The company has a market cap of $110.86 million, a price-to-earnings ratio of -7.40 and a beta of 1.00. electroCore, Inc. has a 12 month low of $4.41 and a 12 month high of $12.70.

electroCore (NASDAQ:ECOR) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.09. electroCore had a negative net margin of 39.96% and a negative return on equity of 1,956.38%. The firm had revenue of $9.45 million during the quarter, compared to analyst estimates of $9.49 million. As a group, equities analysts forecast that electroCore, Inc. will post -1.4 earnings per share for the current year.

Hedge Funds Weigh In On electroCore

A hedge fund recently bought a new position in electroCore stock. WealthShield Partners LLC bought a new position in shares of electroCore, Inc. (NASDAQ:ECOR) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 25,978 shares of the company’s stock, valued at approximately $157,000. WealthShield Partners LLC owned 0.32% of electroCore as of its most recent SEC filing. Hedge funds and other institutional investors own 26.74% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of electroCore in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $18.00.

electroCore Company Profile

electroCore, Inc is a commercial-stage medical device company focused on bioelectronic medicine, an approach that uses electrical signals to influence nerve activity and help manage health conditions. The company develops non-invasive vagus nerve stimulation (nVNS) technologies designed to be used without surgery or implanted devices.

Its primary prescription product is gammaCore, a handheld device that delivers non-invasive vagus nerve stimulation and has been cleared in the United States for the treatment and prevention of certain migraine and cluster headache symptoms.